Øystein’s professional experience is derived from different leadership positions in R&D, Product Management and Business for over 22 years in Thermo Fisher Scientific, he is responsible for development and commercialization of products and services for the cell therapy market. His scientific training is in the field of molecular cell biology and he received a PhD from the University of Oslo. Øystein’s academic career focused on the study of physiological & molecular mechanisms of tumor cell growth and the development of novel therapies for the treatment of solid tumors in collaboration with Norsk Hydro
Also Speaking
Sarah Busch
Vice President of Regenerative Medicine, Head of Nonclinical Development • Athersys
8 November 2022
Marco Ruella
Assistant Professor of Medicine in the Division of Hematology/Oncology and the Center for Cellular Immunotherapies • University of Pennsylvania
30 December 2022
Also Speaking
Investor List
Take a look at some of the investors who attended Advanced Therapies Week 2023.
6 January 2023